[바카라 꽁 머니 USA] K-바카라 꽁 머니 showcases in Boston, the U.S. 바카라 꽁 머니 hub…“Pursuing global partnership expansion”

[by Ji, Yong Jun] A line extending over 30 meters formed in front of the Boston Convention & Exhibition Center in Massachusetts, USA, as global pharmaceutical and biotechnology industry professionals from around the world gathered on the morning of June 16 (local time) to attend the ‘BIO International Convention 2025 (BIO USA)’ in Boston, widely recognized as the world’s largest biotechnology hub.

Over the four-day duration of 바카라 꽁 머니 USA, more than 1,100 experts are expected to engage in in-depth discussions across key areas of 바카라 꽁 머니technology, including artificial intelligence (AI), digital healthcare, next-generation 바카라 꽁 머니therapeutics, and business development (BD). The event has drawn a substantial number of participants not only from the United States but also from the global pharmaceutical and 바카라 꽁 머니technology sectors, contributing to its vibrant atmosphere. According to estimates by the organizing body, the 바카라 꽁 머니technology Innovation Organization (바카라 꽁 머니), representatives from 72 countries are in attendance, with international participants accounting for 46% of the over 20,000 total attendees.

According to a representative from a Korean 바카라 꽁 머니tech firm, the 바카라 꽁 머니 USA convention, once predominantly led by global pharmaceutical companies, has undergone a shift in focus. Today, the primary participants are business development teams, university research groups, national research institutions, and government agencies. This reflects a broader transformation of the event from a platform primarily for corporate promotion to a strategic hub for fostering connections in the global research and innovation ecosystem.

Notably, Chinese companies that had boycotted 바카라 꽁 머니 USA last year have resumed their participation. “There is a growing trend of Chinese 바카라 꽁 머니tech companies gradually rejoining 바카라 꽁 머니 USA,” said Lee Seung-gyu, Vice Chairman of the Korea 바카라 꽁 머니technology Industry Organization (Korea바카라 꽁 머니).

This year, a significant number of participants from Korea’s pharmaceutical and 바카라 꽁 머니technology sector, ranging from large corporations to startups, attended the 바카라 꽁 머니 USA event. According to the Korea 바카라 꽁 머니technology Industry Organization (Korea바카라 꽁 머니), approximately 60 Korean companies took part, including major firms such as Samsung 바카라 꽁 머니logics, Celltrion, SK 바카라 꽁 머니pharmaceuticals, and Lotte 바카라 꽁 머니logics, which operated individual booths. Additionally, 51 companies showcased their technologies through the ‘Korean Pavilion,’ jointly organized by Korea바카라 꽁 머니 and KOTRA.

Samsung 바카라 꽁 머니logics, the only Korean company to have maintained a standalone booth at 바카라 꽁 머니 USA for 13 consecutive years since its founding in 2011, drew attention by installing a 167 m2 booth at the heart of the exhibition hall’s busiest area. This year, in addition to highlighting its global competitiveness in securing orders, the company unveiled ‘Samsung Organoids,’ a newly launched organoid-based drug screening service that marks its expansion into clinical trial contract research organization (CRO) services. “This year, our focus was on promoting organoid services and antibody-drug conjugate (ADC) capabilities,” expressed James Choi, Vice President of Samsung 바카라 꽁 머니logics.

Celltrion is operating a standalone booth of approximately 140 m2 at 바카라 꽁 머니 USA, facilitating contact with numerous global companies through open meeting areas and private conference rooms. The company anticipates holding over 100 meetings during the event. In addition to promoting its established 바카라 꽁 머니similar portfolio, Celltrion aims to explore partnerships for pipeline expansion, with a strategic focus on next-generation ADCs and novel antibody drugs.

SK 바카라 꽁 머니pharmaceuticals set up its first standalone booth at the event, placing emphasis on showcasing its novel drug development capabilities through its epilepsy drug, ‘XCOPRI (cenobamate).’ “Through 바카라 꽁 머니 USA, we aim to reaffirm our company’s innovative novel drug development capabilities and global partnership expansion strategy,” stated Choi Yoon-jung, head of SK 바카라 꽁 머니pharmaceuticals’ business development division. “This year, we intend to pursue more concrete collaborative opportunities and further solidify our position within the global healthcare ecosystem.”

Shin Yoo-yeol, vice President of Lotte Holdings and third-generation heir of the Lotte Group, garnered attention by attending the event alongside Lotte 바카라 꽁 머니logics CEO James Park. Shin and Park personally visited the Korean pavilion, where Korean companies were gathered, and emphasized the importance of expanding partnerships in the field of ADCs.

Major affiliates of Dong-A Socio Holdings, including Dong-A ST, ST Pharm, and STgen 바카라 꽁 머니, also participated with a joint booth, concentrating on promoting their respective competitive strengths. Kyongbo Pharmaceutical, an affiliate of Chong Kun Dang pharmaceutical, signaled its intention for global expansion by introducing ADC CDMO capabilities at this year’s 바카라 꽁 머니 USA.

Korean 바카라 꽁 머니technology companies also placed a strong emphasis on business development (BD) by actively promoting their technologies through one-on-one meetings, rather than operating exhibition booths. During a press conference hosted by the Korea바카라 꽁 머니 on the same day, Vice Chairman Lee Seung-gyu emphasized, “Whereas last year’s focus was primarily on modality (treatment approaches), this year saw participation not only from companies but from across all segments of the 바카라 꽁 머니technology and healthcare industries,” adding, “The global community is increasingly recognizing the importance of the 바카라 꽁 머니tech industry.”